STAT3, the Challenge for Chemotherapeutic and Radiotherapeutic Efficacy

被引：39

作者：

Yang, Ping-Lian ^{[1
,2
]}

Liu, Lu-Xin ^{[1
,3
]}

Li, En-Min ^{[1
,3
]}

Xu, Li-Yan ^{[1
,2
]}

机构：

[1] Shantou Univ, Key Lab Mol Biol High Canc Incidence Coastal Chao, Med Coll, Shantou 515041, Guangdong, Peoples R China

[2] Shantou Univ, Inst Oncol Pathol, Med Coll, Shantou 515041, Guangdong, Peoples R China

[3] Shantou Univ, Dept Biochem & Mol Biol, Med Coll, Shantou 515041, Guangdong, Peoples R China

来源：

CANCERS | 2020年 / 12卷 / 09期

基金：

中国国家自然科学基金;

关键词：

chemoresistance; radioresistance; STAT3; beta; target therapy; RADIATION-INDUCED APOPTOSIS; EPIDERMAL-GROWTH-FACTOR; OVARIAN-CANCER CELLS; TRANSCRIPTION FACTOR STAT3; COLONY-STIMULATING FACTOR; SMALL-MOLECULE INHIBITOR; DNA-BINDING ACTIVITY; SIGNAL TRANSDUCER; PROSTATE-CANCER; CYCLIN D1;

D O I：

10.3390/cancers12092459

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chemoradiotherapy is one of the most effective and extensively used strategies for cancer treatment. Signal transducer and activator of transcription 3 (STAT3) regulates vital biological processes, such as cell proliferation and cell growth. It is constitutively activated in various cancers and limits the application of chemoradiotherapy. Accumulating evidence suggests that STAT3 regulates resistance to chemotherapy and radiotherapy and thereby impairs therapeutic efficacy by mediating its feedback loop and several target genes. The alternative splicing product STAT3 beta is often identified as a dominant-negative regulator, but it enhances sensitivity to chemotherapy and offers a new and challenging approach to reverse therapeutic resistance. We focus here on exploring the role of STAT3 in resistance to receptor tyrosine kinase (RTK) inhibitors and radiotherapy, outlining the potential of targeting STAT3 to overcome chemo(radio)resistance for improving clinical outcomes, and evaluating the importance of STAT3 beta as a potential therapeutic approach to overcomes chemo(radio)resistance. In this review, we discuss some new insights into the effect of STAT3 and its subtype STAT3 beta on chemoradiotherapy sensitivity, and we explore how these insights influence clinical treatment and drug development for cancer.

引用

页码：1 / 31

页数：31

共 233 条

[11] GENOMIC INSTABILITY IN CANCER Strategies to improve radiotherapy with targeted drugs [J].

Begg, Adrian C. ;

Stewart, Fiona A. ;

Vens, Conchita .

NATURE REVIEWS CANCER, 2011, 11 (04) :239-253

[12] Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors [J].

Bendell, Johanna C. ;

Hong, David S. ;

Burris, Howard A., III ;

Naing, Aung ;

Jones, Suzanne F. ;

Falchook, Gerald ;

Bricmont, Patricia ;

Elekes, Agnes ;

Rock, Edwin P. ;

Kurzrock, Razelle .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (01) :125-130

[13] Role of Stat3 in lipopolysaccharide-induced IL-10 gene expression [J].

Benkhart, EM ;

Siedlar, M ;

Wedel, A ;

Werner, T ;

Ziegler-Heitbrock, HWL .

JOURNAL OF IMMUNOLOGY, 2000, 165 (03) :1612-1617

[14] Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia [J].

Biethahn, S ;

Alves, F ;

Wilde, S ;

Hiddemann, W ;

Spiekermann, K .

EXPERIMENTAL HEMATOLOGY, 1999, 27 (05) :885-894

[15] Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line [J].

Biliran, H ;

Wang, Y ;

Banerjee, X ;

Xu, HM ;

Heng, H ;

Thakur, A ;

Bollig, A ;

Sarkar, FH ;

Liao, JD .

CLINICAL CANCER RESEARCH, 2005, 11 (16) :6075-6086

[16] Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3) [J].

Brambilla, Lara ;

Genini, Davide ;

Laurini, Erik ;

Merulla, Jessica ;

Perez, Laurent ;

Fermeglia, Maurizio ;

Carbone, Giuseppina M. ;

Pricl, Sabrina ;

Catapano, Carlo V. .

MOLECULAR ONCOLOGY, 2015, 9 (06) :1194-1206

[17] Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development [J].

Buettner, Ralf ;

Corzano, Renzo ;

Rashid, Rumana ;

Lin, Jianping ;

Senthil, Maheswari ;

Hedvat, Michael ;

Schroeder, Anne ;

Mao, Allen ;

Herrmann, Andreas ;

Yim, John ;

Li, Hongzhi ;

Yuan, Yate-Ching ;

Yakushijin, Kenichi ;

Yakushijin, Fumiko ;

Vaidehi, Nagarajan ;

Moore, Roger ;

Gugiu, Gabriel ;

Lee, Terry D. ;

Yip, Richard ;

Chen, Yuan ;

Jove, Richard ;

Horne, David ;

Williams, John C. .

ACS CHEMICAL BIOLOGY, 2011, 6 (05) :432-443

[18] Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells [J].

Casimiro, Mathew C. ;

Di Sante, Gabriele ;

Ju, Xiaoming ;

Li, Zhiping ;

Chen, Ke ;

Crosariol, Marco ;

Yaman, Ismail ;

Gormley, Michael ;

Meng, Hui ;

Lisanti, Michael P. ;

Pestell, Richard G. .

CANCER RESEARCH, 2016, 76 (02) :329-338

[19] Granulocyte colony-stimulating factor activation of Stat3 alpha and Stat3 beta in immature normal and leukemic human myeloid cells [J].

Chakraborty, A ;

White, SM ;

Schaefer, TS ;

Ball, ED ;

Dyer, KF ;

Tweardy, DJ .

BLOOD, 1996, 88 (07) :2442-2449

[20] Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents [J].

Chen, Haijun ;

Yang, Zhengduo ;

Ding, Chunyong ;

Chu, Lili ;

Zhang, Yusong ;

Terry, Kristin ;

Liu, Huiling ;

Shen, Qiang ;

Zhou, Jia .

ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (02) :180-185

← 1 2 3 4 5 6 7 8 9 10 →